On Wednesday, Shares of Summit Therapeutics plc (NASDAQ: SMMT) surged 3.75% to $1.38. The stock traded total volume of 943 shares lower than the average volume of 49.68K shares.
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, recently reports its financial results for the second quarter and half year ended 31 July 2018.
- Profit for the three months ended 31 July 2018 of £26.60M contrast to a loss of £3.30M for the three months ended 31 July 2017. Profit in the current quarter was driven by the recognition of all deferred revenue related to the Sarepta licence and partnership agreement following the discontinuation of ezutromid development
- Cash and cash equivalents at 31 July 2018 of £17.10M contrast to £20.10M at 31 January 2018.
SMMT has the market capitalization of $109.23M. Price to sales ratio was 1.21 while 21.75% of the stock was owned by institutional investors.